mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

BACKGROUND: Cetuximab, a monoclonal blocking antibody against the epidermal growth factor receptor EGFR, has been approved for the treatment of squamous cell carcinomas of the head and neck (HNSCC). However, only few patients display long-term responses, prompting the search for cetuximab resistance...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wang, Zhiyong, Martin, Daniel, Molinolo, Alfredo A., Patel, Vyomesh, Iglesias-Bartolome, Ramiro, Sol Degese, Maria, Vitale-Cross, Lynn, Chen, Qianming, Gutkind, J. Silvio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133928/
https://ncbi.nlm.nih.gov/pubmed/25099740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju215
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak